Alnylam Pharmaceuticals, Inc. (BVMF:A1LN34)

Market Cap	316.76B
Revenue (ttm)	17.11B
Net Income (ttm)	232.18M
Shares Out	n/a
EPS (ttm)	1.76
PE Ratio	1,364.31
Forward PE	47.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	126
Average Volume	153
Open	120.96
Previous Close	117.70
Day's Range	120.96 - 120.96
52-Week Range	66.50 - 132.40
Beta	0.30
RSI	48.93
Earnings Date	Nov 6, 2025

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 2,230
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: A1LN34

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial numbers in USD